trial

Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia

NCTId NCT00535574
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 90 (actual)
Sponsored by Beersheva Mental Health Center
Primary completion 2010-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
90 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-11
Primary completion
2010-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Bexarotene (Targretin LGD1069)bexarotene

Sponsors

Beersheva Mental Health CenterLead Sponsor

Investigators

1
Prof. Vladimir Lerner, MD, PhDPrincipal Investigator

Sites

3 total
Beersheba, IsraelBat Yam, IsraelHadera, Israel

Linked catalysts

1
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia — primary completion2010-12

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE3
Primary Completion Date
2010-12
Status
COMPLETED
relationships
The graph out of here
drug
Bexarotene (Targretin LGD1069)
drug
bexarotene
drug
lead_sponsor
Beersheva Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Prof. Vladimir Lerner, MD, PhD
person